Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03215277
Previous Study | Return to List | Next Study

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03215277
Recruitment Status : Completed
First Posted : July 12, 2017
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

Brief Summary:
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Drug: Bimekizumab Drug: Certolizumab pegol Other: Placebo Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
Actual Study Start Date : October 4, 2017
Actual Primary Completion Date : May 25, 2020
Actual Study Completion Date : May 25, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Bimekizumab
Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
Drug: Bimekizumab
One bimekizumab dose will be administered.
Other Names:
  • UCB4940
  • BKZ

Other: Placebo
Placebo will be provided to maintain the blinding.

Experimental: Certolizumab pegol
Subjects will receive several certolizumab pegol administrations on pre-defined time points.
Drug: Certolizumab pegol
Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
Other Names:
  • CZP
  • Cimzia
  • CDP870




Primary Outcome Measures :
  1. Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 [ Time Frame: From Baseline to Week 12 ]

    ASDAS is calculated as the sum of the following components:

    • 0.121 x Total spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result)
    • 0.058 x Duration of morning stiffness (BASDAI Question 6 result)
    • 0.110 x Patient's Global Assessment of Disease Activity (PGADA)
    • 0.073 x Peripheral pain/swelling (BASDAI Question 3 result)
    • 0.579 x (natural logarithm of the C-reactive protein (CRP) [mg/L] + 1)

    Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling are all assessed on a numerical scale (0 to 10 units). The results of each of these component calculations are summed to obtain the ASDAS.


  2. Incidence of adverse events (AE) during the study conduct [ Time Frame: From Screening until Safety Follow-Up Visit (up to Week 64) ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

  3. Incidence of serious adverse events (SAEs) during the study conduct [ Time Frame: From Screening until Safety Follow-Up Visit (up to Week 64) ]

    An SAE is any untoward medical occurrence that at any dose:

    • Results in death
    • Is life-threatening
    • Requires in patient hospitalisation or prolongation of existing hospitalisation
    • Is a congenital anomaly or birth defect
    • Is an infection that requires treatment with parenteral antibiotics
    • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above

  4. Number of subjects who withdrew due to an adverse event (AE) during the study conduct [ Time Frame: From Screening until Safety Follow-Up Visit (up to Week 64) ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.


Secondary Outcome Measures :
  1. Percentage of subjects with Ankylosing Spondylitis Disease Activity Score - Inactive Disease (ASDAS-ID) at Week 12 [ Time Frame: Week 12 ]

    ASDAS-ID is defined by ASDAS < 1.3.

    ASDAS is calculated as the sum of the following components:

    • 0.121 x Total spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result)
    • 0.058 x Duration of morning stiffness (BASDAI Question 6 result)
    • 0.110 x Patient's Global Assessment of Disease Activity (PGADA)
    • 0.073 x Peripheral pain/swelling (BASDAI Question 3 result)
    • 0.579 x (natural logarithm of the C-reactive protein (CRP) [mg/L] + 1)

    Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling are all assessed on a numerical scale (0 to 10 units). The results of each of these component calculations are summed to obtain the ASDAS.


  2. Percentage of subjects with Ankylosing Spondylitis Disease Activity Score-Major Improvement (ASDAS-MI) at Week 12 [ Time Frame: Baseline, Week 12 ]

    ASDAS-MI is defined by a reduction (improvement) from Baseline in ASDAS >=2 units.

    ASDAS is calculated as the sum of the following components:

    • 0.121 x Total spinal pain (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 result)
    • 0.058 x Duration of morning stiffness (BASDAI Question 6 result)
    • 0.110 x Patient's Global Assessment of Disease Activity (PGADA)
    • 0.073 x Peripheral pain/swelling (BASDAI Question 3 result)
    • 0.579 x (natural logarithm of the C-reactive protein (CRP) [mg/L] + 1)

    Spinal pain, PGADA, duration of morning stiffness, peripheral pain/swelling are all assessed on a numerical scale (0 to 10 units). The results of each of these component calculations are summed to obtain the ASDAS.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of active adult-onset ankylosing spondylitis (AS) as defined by documented radiologic evidence (X-ray) fulfilling the Modified New York criteria for AS (1984) of at least 3 months' symptom duration and age of onset <45 years
  • Subject has moderate to severe active disease at the Screening Visit as defined by each of the following:

    1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >=4
    2. Spinal pain >=4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
  • Subjects must have had an inadequate response to, have a contraindication to, or have been intolerant to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Subjects taking corticosteroids must be on a maximum daily dose of <=10mg/day oral prednisolone or equivalent
  • Subjects taking methotrexate (MTX; <=25 mg/week) are allowed to continue their medication if they received a stable dose for at least 12 weeks before randomization
  • Subjects taking sulfasalazine (up to 3 grams/day) or hydroxychloroquine (up to 400 mg per day total) are allowed to continue their medication if started at least 12 weeks prior to randomization
  • Subject who has been on an anti-tumor necrosis factor alpha (TNFα) agent must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months or have been intolerant to at least 1 administration of an anti-TNFα agent. Subjects may not have been on more than 1 anti-TNFα agent
  • Subject has high-sensitive C-Reactive Protein (hsCRP) levels >=3 mg/L at the Screening Visit
  • Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of investigational medicinal product (IMP)
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of IMP

Exclusion Criteria:

  • Subject has received previous or current biological treatment other than TNFα inhibitor treatment
  • Subjects with a total ankylosis of the spine, or a diagnosis of any other inflammatory arthritis eg, rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus, or reactive arthritis
  • Subjects with any current sign or symptom that may indicate an active infection (except for the common cold)
  • Subject has received previous or current biological treatment other than TNFα inhibitor treatment
  • Subject has chronic, recurrent, recent serious / life-threatening or current infection, as defined in the protocol
  • Subject has history of certain atypical infections, viral hepatitides, human immunodeficiency virus (HIV) infection, tuberculosis, as defined in the protocol
  • Subjects receiving any live vaccination within the 8 weeks prior to Baseline
  • Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, with latent TB infection or current or history of nontuberculous mycobacteria (NTMB) infection
  • Subject has immunosuppressive condition or treatment, recent history of malignancy (some exceptions) or demyelinating disease
  • Subjects with concurrent malignancy or a history of malignancy during the past 5 years will be excluded, with following exceptions that may be included:

    1. <= 3 excised or ablated basal cell carcinomas of the skin
    2. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised, or ablated only (other treatments, ie, chemotherapy, do not apply), with no signs of recurrence or metastases for more than 2 years prior to Screening
    3. Actinic keratosis (-es)
    4. Squamous cell carcinoma-in-situ of the skin successfully excised, or ablated, more than 6 months prior to Screening
  • Subject has history of psychiatric disorder, including suicidality (as defined in the protocol
  • Subject has major abnormalities on laboratory testing, as defined in the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03215277


Locations
Show Show 34 study locations
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
Layout table for investigator information
Study Director: UCB Cares +1-844-599-2273 (UCB)
Layout table for additonal information
Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT03215277    
Other Study ID Numbers: AS0013
2017-000957-37 ( EudraCT Number )
First Posted: July 12, 2017    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
Ankylosing Spondylitis
Bimekizumab
AS
Certolizumab Pegol
Cimzia
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents